The drug industry may no longer be able to take congressional Republicans' support for granted after the Senate Finance Committee grilled seven company executives on their pricing practices on Tuesday
The drug industry may no longer be able to take congressional Republicans' support for granted after the Senate Finance Committee grilled seven company executives on their pricing practices on Tuesday.
The tone was a marked change from past debates, in which drug companies largely avoided blame from Republicans for surging health costs and warned lawmakers against imposing regulations that the industry said would threaten research on cures. Meanwhile, Sen. Bill Cassidy came close to endorsing Democrats’ call for government negotiations for drugs in Medicare.
Cassidy said it was an example of how middlemen in the drug supply chain who are supposed to lower prices in Medicare aren't effective negotiators. He also endorsed President Donald Trump’s plan to base the price of drugs physicians administer on the lower costs paid in government-run health systems abroad — an idea most Republicans dismiss as anathema to free-market principles.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Drugmakers’ CEOs clash with senators in hearing on drug price hikesExecutives from seven pharmaceutical giants endure grillings but also push back Tuesday on Capitol Hill, as they testify before the Senate Finance Committee about rising drug prices.
Baca lebih lajut »
Sen. Grassley says probe of 'secretive' drug industry pricing won't stop with drugmakersSenate Finance Committee Chairman Chuck Grassley said there needs to be more transparency into how drug prices are set, a system which he said seems to be 'a great deal of secrecy.'
Baca lebih lajut »
Big Pharma companies defending skyrocketing prices on the HillAmericans spent more than $300 billion on prescription drugs last year alone and that’s set to get even higher. Right now, the heads of seven major pharmaceutical companies are on Capitol Hill, trying to defend the skyrocketing costs. Ali Velshi and Stephanie Ruhle are joined by Hippo’s Chief Patient Advocate, MJ Hegar, who claims to have the answer to all of this.
Baca lebih lajut »
Pharma companies wants the government to do something about high drug prices, so long as it's not forcing them to lower their drug pricesPharmaceutical executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower drug prices.
Baca lebih lajut »
Don't expect the Trump administration's newest drug pricing plan to lower all US drug prices yet, 7 pharma execs just told CongressSeven top pharma executives said they were in support of lowering drug prices. But they also had certain conditions.
Baca lebih lajut »
Pharmaceutical Industry CEOs Face Senate Hearing on Drug PricesExecutives for some of the biggest drug companies will visit Capitol Hill on Tuesday to face tough questions in a Senate hearing on the rising cost of medicines.
Baca lebih lajut »
Hearings on 'sky-high' drug prices show how little has changed in 60 yearsThe subjects likely to surface at Tuesday's Senate hearings -- high drug prices and profits, limited price transparency, aggressive marketing, alleged patent abuse and mediocre, 'me-too' drugs -- are identical to the issues senators investigated decades ago.
Baca lebih lajut »
Japanese firms see flat business spending amid trade frictions, tax hike jittersBusiness investment in Japan has been a rare bright spot in the world's thi...
Baca lebih lajut »